Colchicine revisited

Anupama Bhat; Stanley M Naguwa; Gurtej S. Cheema; M. Eric Gershwin

doi:10.1111/j.1749-6632.2009.04674.x

Colchicine revisited

Anupama Bhat, Stanley M Naguwa, Gurtej S. Cheema, M. Eric Gershwin

Rheumatology, Allergy, and Clinical Immunology

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

46 Scopus citations

Abstract

Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.

Original language	English (US)
Title of host publication	Annals of the New York Academy of Sciences
Pages	766-773
Number of pages	8
Volume	1173
DOIs	https://doi.org/10.1111/j.1749-6632.2009.04674.x
State	Published - Sep 2009

Publication series

Name	Annals of the New York Academy of Sciences
Volume	1173
ISSN (Print)	00778923
ISSN (Electronic)	17496632

Keywords

Arthritis
Gout
Uric acid

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1111/j.1749-6632.2009.04674.x

Fingerprint Dive into the research topics of 'Colchicine revisited'. Together they form a unique fingerprint.

Cite this

Bhat, A., Naguwa, S. M., Cheema, G. S., & Gershwin, M. E. (2009). Colchicine revisited. In Annals of the New York Academy of Sciences (Vol. 1173, pp. 766-773). (Annals of the New York Academy of Sciences; Vol. 1173). https://doi.org/10.1111/j.1749-6632.2009.04674.x

@inproceedings{7c5250e483084c13a4054f17cec201f0,

title = "Colchicine revisited",

abstract = "Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Beh{\c c}et's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.",

keywords = "Arthritis, Gout, Uric acid",

author = "Anupama Bhat and Naguwa, {Stanley M} and Cheema, {Gurtej S.} and Gershwin, {M. Eric}",

year = "2009",

month = sep,

doi = "10.1111/j.1749-6632.2009.04674.x",

language = "English (US)",

isbn = "9781573317627",

volume = "1173",

series = "Annals of the New York Academy of Sciences",

pages = "766--773",

booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Colchicine revisited

AU - Bhat, Anupama

AU - Naguwa, Stanley M

AU - Cheema, Gurtej S.

AU - Gershwin, M. Eric

PY - 2009/9

Y1 - 2009/9

N2 - Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.

AB - Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.

KW - Arthritis

KW - Gout

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=69949135704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949135704&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.04674.x

DO - 10.1111/j.1749-6632.2009.04674.x

M3 - Conference contribution

C2 - 19758227

AN - SCOPUS:69949135704

SN - 9781573317627

VL - 1173

T3 - Annals of the New York Academy of Sciences

SP - 766

EP - 773

BT - Annals of the New York Academy of Sciences

ER -